Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.62 |
| ▸ | PRKCG | P05129 | 5/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.62 |
| ▸ | PRKCB | P05771 | 4/20 | 0.62 |
| ▸ | PRKCH | P24723 | 4/20 | 0.62 |
| ▸ | PRKCI | P41743 | 4/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614871 | 0.91 | PRKCA (0.63) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL2413670 | 0.87 | PRKCA (0.79) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL18399979 | 0.87 | PRKCA (0.79) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL18622646 | 0.87 | PRKCA (0.79) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL29370914 | 0.87 | PRKCA (0.79) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL82376 | 0.86 | PRKCA (0.63) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL6907121 | 0.86 | PRKCA (0.64) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL9097599 | 0.83 | PRKCA (0.63) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL28498206 | 0.82 | PRKCA (0.51) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| SCHEMBL9099984 | 0.82 | PRKCA (0.63) | PRKCAPRKCGPRKD3PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220030851-A1 | MODULATING ISCHEMIC INJURY | STEMNION, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-2968402-B1 | MEDICAL DEVICE HAVING A COATING COMPRISING ACCS | NOVEOME BIOTHERAPEUTICS INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190277852-A1 | Method for Determining Prognosis of Cancer | QUEEN MARY UNIVERSITY OF LONDON (GB) | 2019-09-12 | — | — | US | disclosed |
| US-10251897-B2 | GLUT4 endocytosis inhibitor | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180288998-A1 | Modulating Ischemic Injury | Noveome Biotherapeutics, Inc. (US) | 2018-10-11 | — | — | US | disclosed |
| US-9669062-B2 | Molecular and herbal combinations for treating psoriasis | SIRBAL LTD. (CY) | 2017-06-06 | — | — | US | disclosed |
| US-9662417-B2 | Medical device | STEMNION, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160331769-A1 | GLUT4 ENDOCYTOSIS INHIBITOR | NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160220617-A1 | Methods for treating cartilage disorders, diseases and injuries | Noveome Biotherapeutics, Inc. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160113983-A1 | Molecular and Herbal Combinations for Treating Psoriasis | SIRBAL LTD. (CY) | 2016-04-28 | — | — | US | disclosed |
| US-7288631-B2 | For screening of agonists and antagonists of receptor which may have advantageous pharmaceutical or diagnostical properties; for identification of patients who may present genetic disorders induced by inactive receptor | EUROSCREEN, S.A. (BE) | 2007-10-30 | — | — | US | disclosed |
| US-7264940-B2 | G-coupled receptor showing selective affinity for ATP | EUROSCREEN, SAL (BE) | 2007-09-04 | — | — | US | disclosed |
| EP-1450832-B1 | LACTIC ACID BACTERIA AND THEIR USE FOR TREATING AND PREVENTING CANCER | BIO K PLUS INTERNATIONAL INC (CA) | 2006-08-16 | — | — | EP | disclosed |
| US-20060160149-A1 | G-coupled receptor showing selective affinity for ATP | EUROSCREEN, S.A. | 2006-07-20 | — | — | US | disclosed |
| US-7045345-B2 | G-coupled receptor showing selective affinity for ATP | EUROSCREEN, S.A. (BE) | 2006-05-16 | — | — | US | disclosed |
| US-20050208033-A1 | Lactic acid bacteria and their use for treating and preventing cancer | BIO-K PLUS INTERNATIONAL INC. (CA) | 2005-09-22 | — | — | US | disclosed |
| US-20050203282-A1 | G-coupled receptor showing selective affinity for ATP | EUROSCREEN, S.A. | 2005-09-15 | — | — | US | disclosed |
| US-20050158800-A1 | G-coupled receptor showing selective affinity for ATP | EUROSCREEN, S.A. | 2005-07-21 | — | — | US | disclosed |
| US-20020142988-A1 | G-coupled receptor showing selective affinity for ATP | EUROSCREEN, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-5597798-A | Taxol and epidermal growth factor used to enhance treatment of ovarian cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251897-B2 | GLUT4 endocytosis inhibitor | SLC2A4, SLC2A1, SLC2A3 | PRKCA 36/4885PRKCG 55/4885PRKD3 234/4885 |
| US-20160331769-A1 | GLUT4 ENDOCYTOSIS INHIBITOR | SLC2A4, SLC2A1, SLC2A3 | PRKCA 36/4885PRKCG 55/4885PRKD3 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.